MedInCell Stock Jumps 11% in a Week, Reaching a Key Technical Zone
The stock of the biotech company from Montpellier is trading at 23.34 euros this Wednesday, showing a weekly rebound of over 11%. This dynamic contrasts with a market environment characterized by high stress levels, while the CAC 40 is up 2.12% during the session.
MedInCell stock has gained 3.55% compared to the previous day's close, driven by a catch-up movement that started a week ago (+11.78%). The stock had indeed lost more than 7% over the last three months, widening the gap with its long-term moving averages. This rebound now brings the price immediately in contact with the 50-day moving average (23.39 euros) and the 200-day average (23.46 euros), both currently acting as a pivotal zone. A sustained crossing of this zone would pave the way towards the resistance identified at 24.94 euros. The RSI, positioned at 51, indicates a balance between buying and selling pressures, without excess in either direction. Over a year, the performance remains remarkable at +62.08%, reflecting the market's gradual revaluation of the stock since spring 2025. Among comparable pharmaceutical sector stocks, UCB is up 3.17% in the session, while Sanofi advances more modestly by 0.42%.
Key Dates in the Financial Calendar
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The company's financial calendar is an essential reference point for the coming weeks. The publication of the annual results for the fiscal year 2025-2026 is scheduled for June 16, 2026, an event that will allow the assessment of commercial progress and financial trajectory of the biotech specialized in long-duration injection technologies. The general meeting will then be held on September 10, 2026, followed by the communication of the results for the first half of 2026-2027 on December 8. The negative beta of the stock (-0.14) also highlights its low correlation with major indices, partly explaining its ability to perform independently of the tense macroeconomic and geopolitical context. The volatility measured over a month reaches 14.58%, a moderate level for a stock in this segment. The nearest technical support is located at 20.24 euros, providing a cushion of more than 13% below the current price.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
